Industry
Biotechnology
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
February 08, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
February 08, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Insights
February 08, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 9:24 pm
Portfolio Pulse from Benzinga Newsdesk
November 02, 2023 | 2:05 pm
Portfolio Pulse from Charles Gross
September 10, 2023 | 2:27 pm
Portfolio Pulse from Charles Gross
September 10, 2023 | 2:24 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.